FDA Calendar

Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates.

Exact Dates

Estimated Dates

Get Alert
IXCHIQ
For chikungunya virus
08/25/2025
9:36 AM
Provided Update

FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication

View
IGC-AD1
For Agitation in Alzheimer's disease.
Phase 2
08/25/2025
9:34 AM
Provided Update

IGC Pharma, Inc announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma.

View
AMGN
Amgen Inc
Repatha (Evolocumab)
HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events
08/25/2025
9:33 AM
FDA Approval

Amgen announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.'

View
PDSB
PDS Biotechnology Corp
VERSATILE-002
Treatment of recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer.
Phase 2
08/25/2025
8:37 AM
Survival data

PDS Biotechnology announced final topline survival data from its VERSATILE-002 Phase 2 clinical trial. VERSATILE-002 evaluated PDS0101 (Versamune® HPV) + Keytruda® (pembrolizumab) in patients with HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer ("1L R/M HNSCC").

View
BFFTFBFRA
Biofrontera AG
Ameluz
For treatment of actinic keratosis
Phase 2b
08/25/2025
8:25 AM
evaluation

Biofrontera Inc. announced that the final patient in its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris (AV) completed participation on August 22, 2025.

View
CPRX
Catalyst Pharmaceuticals Inc
FIRDAPSE®
For the treatment of LEMS
08/25/2025
8:16 AM
Provided Update

Catalyst Pharmaceuticals, Inc. announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement ("Agreement") with Lupin Ltd and Lupin Pharmaceuticals, Inc. (collectively, "Lupin").

View
AMRN
Amarin Corp PLC
VASCEPA/VAZKEPA (icosapent ethyl)
Prior Peripheral Artery Disease (PAD)
08/25/2025
8:14 AM
Presentation

Amarin Corporation plc announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new data will further illuminate the multifaceted cardioprotective effects of icosapent ethyl (IPE).

View
NTRA
Natera Inc
Signatera
MRD Test for cancer therapies
08/25/2025
8:13 AM
New Data

Natera, Inc announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain.

View
COYA 302
For the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Investigational New Drug (IND)
08/25/2025
8:12 AM
FDA Accepted

Coya Therapeutics, announces that the U.S. Food and Drug Administration ("FDA" or the "Agency") has accepted its Investigational New Drug (IND) application for COYA 302.

View
EOLS
Evolus Inc
Evolysse™
Evolus dermal filler,
08/25/2025
8:11 AM
Top-line results

Evolus, Inc announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.

View
ARTL
Artelo Biosciences Inc
ART26.12
For the prevention of chemotherapy-induced peripheral neuropathy, a debilitating and often treatment-altering side effect of cancer therapy.
08/25/2025
7:35 AM
Results

Artelo Biosciences, Inc. announced encouraging results from its preliminary food effect evaluation with ART26.12.

View
BBIO
BridgeBio Pharma Inc
Acoramidis (ATTRibute-CM)
Symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM)
08/25/2025
7:35 AM
Oral presentation

BridgeBio Pharma, Inc. announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025.

View
CYTK
Cytokinetics Inc
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
08/25/2025
7:32 AM
Presentation

Cytokinetics announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1, 2025 including a Hot Line presentation of the primary results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) and a Late Breaking Clinical Science presentation relating to the incidence and impact of atrial fibrillation across three clinical trials of aficamten in obstructive hypertrophic cardiomyopathy (HCM).

View
ALKS
Alkermes PLC
ALKS 2680
For the treatment of narcolepsy
08/25/2025
7:18 AM
presented results

Alkermes plc announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place Sept. 5-10, 2025 in Singapore, and in an investor webcast presentation hosted by the company.

View
SION
Sionna Therapeutics Inc
SION-451
cystic fibrosis transmembrane conductance regulator (CFTR) protein
Phase 1
08/25/2025
7:17 AM
Dose Update

Sionna Therapeutics, announced that the first subjects have been dosed in a Phase 1 trial evaluating SION-451, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, in proprietary dual combinations with SION-2222 (galicaftor), a transmembrane domain 1 (TMD1)-directed CFTR corrector, and with SION-109, an intracellular loop 4 (ICL4)-directed CFTR corrector.

View
CSTL
Castle Biosciences Inc
DecisionDx-SCC
High-risk cutaneous squamous cell carcinoma (SCC)
08/25/2025
7:16 AM
Publication

Castle Biosciences, announced the publication of two new studies related to its DecisionDx-SCC test, adding to its validated uses for patients with high-risk cutaneous squamous cell carcinoma (SCC).1,2 DecisionDx-SCC is a gene expression profile test (40-GEP) designed to use a patient's tumor biology to predict individual risk of metastasis as well as response to adjuvant radiation therapy (ART).

View
PTGX
Protagonist Therapeutics Inc
Rusfertide (PTG-300)
Polycythemia vera (PV)
Breakthrough Therapy Designation
08/25/2025
7:15 AM
Designation Grant

Protagonist Therapeutic announced today that rusfertide, a potential first-in-class hepcidin-mimetic peptide, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of erythrocytosis in patients with polycythemia vera (PV).

View
SBBPXERS
Strongbridge Biopharma PLC
Xeris Pharmaceuticals Inc
RECORLEV (levoketoconazole)
Endogenous Cushing's syndrome
08/25/2025
7:14 AM
Provided Update

Xeris Biopharma Holdings, Inc announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and that this patent is now listed in the publication, "Approved Drug Products with Therapeutics Equivalence Evaluations," commonly known as the "Orange Book."

View
LIANBMYBMYMP
LianBio
Bristol-Myers Squibb Company
CAMZYOS® (mavacamten)
For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy
08/25/2025
7:13 AM
Presentation

Bristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology(ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain.

View
MRK
Merck & Co Inc
VERQUVO (vericiguat)
Chronic Heart Failure and Reduced Ejection Fraction
08/25/2025
7:11 AM
Clinical Trial

Merck announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain from August 29 – September 1.

View
TBPH
Theravance Biopharma Inc
Ampreloxetine
Symptomatic neurogenic orthostatic hypotension
Phase 3
08/25/2025
7:05 AM
Enrollment Completion

Theravance Biopharma, Inc. announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder.

View
BIIB
Biogen Inc
Lecanemab (BAN2401)
Anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD)
08/25/2025
3:05 AM
Provided Update

Eisai Co., and Biogen Inc. announced today that the anti-amyloid beta (Aβ) monoclonal antibody "LEQEMBI®" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025.

View
ARGNFARGX
argenx SE
VYVGART (efgartigimod alfa)
For Adults with Primary Immune Thrombocytopenia
08/25/2025
1:45 AM
Top-line data

argenx SE announced positive topline data from the pivotal ADAPT SERON study of VYVGART® (IV: efgartigimod alfa-fcab).

View
MRNA
Moderna Inc
SPIKEVAX (COVID-19 Vaccine, mRNA)
COVID-19 in individuals 18 years of age and older
Health Canada
08/22/2025
9:25 AM
Authorization

Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older.

View
CTXR
Citius Pharmaceuticals Inc
LYMPHIR
For the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
08/22/2025
8:50 AM
Provided Update

Citius Oncology, Inc the oncology-focused subsidiary of Citius Pharmaceuticals, Inc announced that it has deployed an innovative AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL).

View
STTK
Shattuck Labs Inc
SL-325
In inflammatory bowel disease
Investigational New Drug (IND)
08/21/2025
2:22 AM
Provided Update

Shattuck Labs, Inc announced that the Company's Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) for SL-325 for the treatment of inflammatory bowel disease is in effect. SL-325, a potentially first-in-class DR3 blocking antibody, is a fully Fc-silenced humanized immunoglobulin G monoclonal antibody, demonstrated high-affinity binding to human DR3 and potent inhibition of TL1A binding to DR3 in preclinical studies, and a favorable safety profile in non-human primate studies.

View
JAGX
Jaguar Health Inc
Canalevia-CA1
For the treatment of chemotherapy-induced diarrhea (CID) in dogs.
08/21/2025
9:03 AM
Provided Update

Jaguar Health, Inc announced it is participating in the 2025 Animal Health Summit in support of the company's goal of securing a collaboration to expand the indication of Canalevia (crofelemer delayed-release tablets) from treatment of chemotherapy-induced diarrhea (CID) in dogs to treatment of general diarrhea in dogs..

View
CRNX
Crinetics Pharmaceuticals Inc
Atumelnant
In Congenital Adrenal Hyperplasia (CAH)
Orphan Drug Designation
08/21/2025
8:45 AM
Designation Grant

Crinetics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH).

View
ABBV
AbbVie Inc
RINVOQ (upadacitinib)
Moderate to Severe Atopic Dermatitis
08/21/2025
8:43 AM
Top-line results

AbbVie announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage).1

View
SEPN
Septerna Inc
SEP-631
For Mast Cell Diseases
Phase 1
08/21/2025
8:41 AM
Dosing Update

Septerna, announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases.

View
TYRA-300
For the Treatment of Achondroplasia
Phase 2
08/21/2025
8:39 AM
Dose Update

Tyra Biosciences, Inc. announced today that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism.

View
DVAX
Dynavax Technologies Corp
Z-1018
Shingles Vaccine Profile
Phase 1/2
08/21/2025
8:37 AM
Top-line results

Dynavax Technologies announced positive topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years.

View
PTIX
Protagenic Therapeutics Inc
PT00114
Depression, PTSD, Anxiety and Addiction
08/21/2025
8:22 AM
Dosing Update

Protagenic Therapeutics, Inc. announced completion of first dose injection for all study subjects in the multiple-dose portion of its ongoing Phase I clinical trial of PT00114.

View
EVOK
Evoke Pharma Inc
GIMOTI (metoclopramide) nasal spray
Acute and recurrent diabetic gastroparesis
08/21/2025
7:33 AM
Provided Update

Evoke Pharma, Inc. announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the "Orange Book".

View
PRTCPTCHF
PureTech Health PLC
LYT-100
Idiopathic Pulmonary Fibrosis
08/21/2025
7:31 AM
Provided Update

PureTech Health plc demonstrated its growing leadership in idiopathic pulmonary fibrosis (IPF) at the 2025 IPF Summit this week in Boston. The Company highlighted the strength of its Phase 2b ELEVATE IPF trial data supporting the advancement of deupirfenidone (LYT-100) into Phase 3 by its newest Founded Entity, Celea Therapeutics ("Celea"), and shared new patient preference data and insights shaped by deep engagement across the IPF treatment ecosystem.

View
REGN
Regeneron Pharmaceuticals Inc
EYLEA (aflibercept)
Wet age-related macular degeneration (wet AMD)
European Commission Approval
08/21/2025
4:49 AM
Approved

Alvotech announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept), in a pre-filled syringe and vial.

View
RYTM
Rhythm Pharmaceuticals Inc
Setmelanotide (HO)
Hypothalamic Obesity
supplemental New Drug Application (sNDA)
08/20/2025
1:58 AM
FDA Accepted

Rhythm Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's supplemental New Drug Application (sNDA) for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity.

View
SVRA
Savara Inc
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Phase 2
08/20/2025
1:54 AM
Results

Savara Inc. announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM.

View
TH104
For Chronic Pruritis in Primary Biliary Cholangitis (PBC)
08/20/2025
8:47 AM
Positive Results

Tharimmune, Inc. announced positive results from a recent pharmacokinetic (PK) simulation analysis of its lead clinical asset, TH104, a buccal film formulation of nalmefene.

View
EOLS
Evolus Inc
Evolysse™
Evolus dermal filler,
08/20/2025
8:46 AM
Application Submitted

Evolus, Inc. announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.

View
BMYBMYMP
Bristol-Myers Squibb Company
Opdivo (nivolumab)
Resected esophageal or gastroesophageal junction (GEJ) cancer in the adjuvant setting
08/20/2025
8:43 AM
FDA Approval

Agilent Technologies Inc. announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb's Opdivo® (nivolumab) alone or Opdivo (nivolumab) in combination with Yervoy® (ipilimumab).

View
RCKT
Rocket Pharmaceuticals Inc
RP-A501
Danon Disease
08/20/2025
7:11 AM
Lifted Clinical Hold

Rocket Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.

View
NVCR
NovoCure Ltd
Tumor Treating Fields - PANOVA-3
Locally advanced pancreatic cancer
08/20/2025
7:09 AM
Application Submitted

Novocure announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer.

View
PFE
Pfizer Inc
PAXLOVID
Covid-19
08/20/2025
7:08 AM
Provided Update

Enanta Pharmaceuticals, Inc announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets).

View
CTSO
CytoSorbents Corp
DrugSorb-ATR
Antithrombotic Removal System
08/20/2025
7:07 AM
Regulatory Update

CytoSorbents Corporation updates the regulatory status of its appeal with the U.S. Food and Drug Administration (FDA) for De Novo market authorization of DrugSorb™-ATR.

View
CLDX
Celldex Therapeutics Inc
Barzolvolimab
For Prurigo Nodularis
Phase 2
08/19/2025
2:19 AM
Top-line results

Celldex Therapeutics, Inc today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.

View
MDGL
Madrigal Pharmaceuticals Inc
Rezdiffra (resmetirom)
for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
European Commission Conditional Marketing Authorization
08/19/2025
2:19 AM
Marketing authorization

Madrigal Pharmaceuticals, Inc announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

HCM
HUTCHMED (China) Limited
SANOVO
for Certain Lung Cancer Patients
Phase 3
08/19/2025
2:11 AM
Enrollment Completion

HUTCHMED (China) Limited announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer ("NSCLC") patients whose tumors harbor epidermal growth factor receptor ("EGFR") mutation and MET overexpression. The last patient was enrolled on August 18, 2025.

View
JAGX
Jaguar Health Inc
Crofelemer
Microvillus inclusion disease (MVID) - Rare congenital diarrheal disorder
08/19/2025
9:04 AM
Provided Update

Jaguar Health, Inc. announced that it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the company's ongoing clinical development program for crofelemerfor the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder.

View
tafenoquine
For treatment of babesiosis
Phase 2
08/19/2025
8:54 AM
Provided Update

60 Degrees Pharmaceuticals, announced today it has signed a clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York City as the central site for a Phase II clinical study of tafenoquine in treating chronic babesiosis.

View
MREO
Mereo BioPharma Group PLC
Vantictumab
for Autosomal Dominant Osteopetrosis Type 2
08/19/2025
8:36 AM
Provided Update

āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced an exclusive licensing agreement with Mereo BioPharma for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare, debilitating bone disorder with no approved therapies.

View
ANKTIVA
For Bacillus Calmette-Guérin
Phase 3
08/19/2025
8:35 AM
Provided Update

ImmunityBio, Inc announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients with long COVID.

View
DCTH
Delcath Systems Inc
HEPZATO KIT
For the treatment of metastatic uveal melanoma (mUM).
Phase 2
08/19/2025
8:33 AM
Dose Update

Delcath Systems, Inc. announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment for liver-dominant metastatic colorectal cancer (mCRC).

View
MIRA
MIRA PHARMACEUTICALS, INC.
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
Phase 1
08/19/2025
8:32 AM
Dose Update

MIRA Pharmaceuticals, Inc. announced the successful completion of the Single Ascending Dose (SAD) portion of its ongoing Phase 1 clinical trial evaluating oral Ketamir-2.

View
PHGEPHGE.U
BiomX Inc
BX004
Cystic Fibrosis
Phase 2b
08/19/2025
8:19 AM
Clinical Hold

BiomX Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Phase 2b trial of BX004 for the treatment of patients with cystic fibrosis (CF).

View
SILO
SILO Pharma Inc
SPC-15
Treatment for PTSD
08/19/2025
8:17 AM
Results

Silo Pharma, Inc. announced positive bioanalytical and safety/toxicology results for its U.S. Food and Drug Administration (FDA)-requested 7-day large animal safety study of its lead asset SPC-15.

View
ALRN
Aileron Therapeutics Inc
LTI-03
In Idiopathic Pulmonary Fibrosis
Phase 2
08/19/2025
8:03 AM
Clinical Trial

Rein Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 "RENEW" clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF).

View
ALXO
ALX Oncology Holdings Inc
ALX2004
For the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors
08/19/2025
8:02 AM
Dose Update

ALX Oncology Holdings Inc announced that the first patient has been dosed in the Company's Phase 1 clinical trial for ALX2004, a potential best- and first-in-class, epidermal growth factor receptor (EGFR) ADC that is being studied for the treatment of EGFR-expressing solid tumors.

View
ALT
Altimmune Inc
pemvidutide
for the treatment of obesity and MASH
Fast Track Designation
08/19/2025
7:38 AM
Decision Deferred

Altimmune, Inc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD).

View
VKTX
Viking Therapeutics Inc
VK2735
Metabolic disorders
Phase 2
08/19/2025
7:24 AM
Top-line results

Viking Therapeutics, Inc. announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

View
ALDX
Aldeyra Therapeutics Inc
ADX-2191
Primary vitreoretinal lymphoma (PVRL)
Fast Track Designation
08/19/2025
7:23 AM
Designation Grant

Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa.

View
BTAI
BioXcel Therapeutics Inc
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
Phase 3
08/19/2025
7:15 AM
Provided Update

BioXcel Therapeutics announced completion of the database lock for its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. Topline results from the study are expected in August.

View
RGNX
Regenxbio Inc
RGX-121
MPS II (Hunter Syndrome)
Biologics License Applications (BLA)
08/18/2025
2:38 AM
Provided Update

REGENXBIO Inc. announced that the U.S. Food and Drug Administration (FDA) extended its review timeline of the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.

View
VYD2311
Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
08/18/2025
2:37 AM
Data

Invivyd, Inc. announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA® (pemivibart) against the currently dominant and growing XFG variant of SARS-CoV-2. Notably, and consistent with all dominant variants for the past three years, XFG did not generate any meaningful change to the in vitro neutralization activity of pemivibart or VYD2311, the company's next generation COVID-19 monoclonal antibody (mAb) candidate, as the epitopes targeted by pemivibart and VYD2311 remain structurally intact.

View
IOVA
Iovance Biotherapeutics Inc
Lifileucel
For the Treatment of Advanced Melanoma
08/18/2025
2:31 AM
Notice of Compliance

Iovance Biotherapeutics, announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi® (lifileucel), a tumor-derived autologous T cell immunotherapy.

View
MMSI
Merit Medical Systems Inc
WRAPSODY
Cell-Impermeable Endoprosthesis (CIE).
08/18/2025
2:24 AM
Enrollment Update

Merit Medical Systems announced today the successful enrollment of the first patient in the WRAP North America registry.

View
CAPR
Capricor Therapeutics Inc
StealthX
exosome-based vaccine.
Phase 1
08/18/2025
9:02 AM
Dose Update

Capricor Therapeutics announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vaccine.

View
eRapa
In Familial Adenomatous Polyposis
08/18/2025
8:34 AM
Enrollment Update

Biodexa Pharmaceuticals PLC is pleased to announce the enrolment of the first two patients by the Pan American Center for Oncology Trials in San Juan, Puerto Rico into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer.

View
NMTC
NeuroOne Medical Technologies Corp
OneRF
Ablation System for creation of radiofrequency ("RF") lesions in nervous tissue for functional neurosurgical procedures.
08/18/2025
8:31 AM
FDA Clearance

NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Administration ("FDA") clearance to market its OneRF® Trigeminal Nerve Ablation System for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures.

View
RDY
Dr Reddy's Laboratories Ltd
Carac
For the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
08/18/2025
8:17 AM
Launch

Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's Laboratories Ltd. announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).

View
SVRA
Savara Inc
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
08/18/2025
8:13 AM
FDA Accepted

Savara Inc announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025, September 27 – October 1, Amsterdam, The Netherlands.

View
IRD
Opus Genetics
OPGx-BEST1
For the treatment of bestrophin-1 (BEST1)-related IRD.
Investigational New Drug (IND)
08/18/2025
8:07 AM
FDA Accepted

Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related IRD.

View
RARE
Ultragenyx Pharmaceutical Inc
DTX401 AAV
For the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Biologics License Applications (BLA)
08/18/2025
8:02 AM
rolling submission

Ultragenyx Pharmaceutical announced the initiation of a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for DTX401 AAV gene therapy as a treatment for Glycogen Storage Disease Type Ia (GSDIa).

View
ENLV
Enlivex Therapeutics Ltd
Allocetra
Sepsis
08/18/2025
7:58 AM
Top-line results

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

View
SNGX
Soligenix Inc
SGX945
In the Treatment of Aphthous Ulcers in Behçet's Disease
Orphan Drug Designation
08/18/2025
7:33 AM
Designation Grant

Soligenix, Inc. announced that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for "treatment of Behçet's Disease" following review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet's Disease.

View
PSTV
Plus Therapeutics Inc
REYOBIQ™
For Patients with Leptomeningeal Metastases
Phase 1
08/18/2025
7:32 AM
Positive Data

Plus Therapeutics, Inc. announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the podium at the SNO/ASCO CNS Metastases Conference in Baltimore, MD.

View
UNI-494
In the progression of acute kidney injury and chronic kidney disease.
08/18/2025
7:14 AM
Provided Update

Unicycive Therapeutics, announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for UNI-494 to treat Chronic Kidney Disease (CKD). This patent follows the issuance of an earlier method of use patent for the treatment of Acute Kidney Injury with UNI-494.

View
VNDA
Vanda Pharmaceuticals Inc
HETLIOZ
For treat jet lag disorder
08/18/2025
7:09 AM
Regulatory Update

Vanda Pharmaceuticals Inc. announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding the approvability of HETLIOZ® (tasimelteon) to treat jet lag disorder (Vanda Pharmaceuticals Inc. v. FDA, case no. 24-1049).

View
LH
Labcorp
Lumipulse®
Blood Test for Alzheimer's Disease
08/18/2025
7:08 AM
Provided Update

Labcorp announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients.

View
BTAI
BioXcel Therapeutics Inc
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
supplemental New Drug Application (sNDA)
08/18/2025
7:05 AM
Positive Opinion

BioXcel Therapeutics, announced that it has received positive pre-sNDA meeting responses from the U.S. Food and Drug Administration (FDA).

View
MRK
Merck & Co Inc
I-DXd
In patients with pretreated extensive-stage small cell lung cancer (ES-SCLC).
Breakthrough Therapy Designation
08/18/2025
7:03 AM
Designation Grant

Daiichi Sankyo and Merck announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.

View
PFE
Pfizer Inc
PAXLOVID
Covid-19
Phase 2
08/18/2025
7:02 AM
evaluation

Traws Pharma, Inc. announced receipt from the Human Research Ethics Committee (HREC) of approval to proceed with a Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID subjects.

View
BMYBMYMP
Bristol-Myers Squibb Company
iza-bren
For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Breakthrough Therapy Designation
08/18/2025
6:25 AM
Designation Grant

SystImmune Inc. and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.

View
NTRA
Natera Inc
IMvigor011
In Muscle-Invasive Bladder Cancer
Phase 3
08/18/2025
6:22 AM
Positive Results

Natera, Inc. announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group.

View
AAPG
Ascentage Pharma
lisaftoclax
In Venetoclax-Refractory Patients
08/17/2025
2:27 AM
FDA Clearance

Ascentage Pharma announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

View
NONOFNVOVERU
Novo Nordisk A/S
Veru Inc
Wegovy
For cardiovascular risk reduction in adults with known heart disease and overweight or obesity
08/15/2025
2:24 AM
FDA approved

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® (semaglutide) injection 2.4 mg, making it the first and only glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity.1

View
TNXP
Tonix Pharmaceuticals Holding Corp
Tonmya
For the management of fibromyalgia.
08/15/2025
4:22 PM
FDA approved

Tonix Pharmaceuticals Holding Corp announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults.

View
GBT
Global Blood Therapeutics Inc
Inclacumab + GBT601
Sickle Cell Disease
Phase 3
08/15/2025
4:19 PM
Results

Pfizer Inc announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease (SCD).

View
BIOA
BioAge Labs Inc
BGE-102
For the treatment of obesity.
Phase 1
08/15/2025
9:01 AM
Dose Update

BioAge Labs, Inc. announced that the first participant has been dosed in a Phase 1 clinical trial evaluating BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration being developed initially for the treatment of obesity.

View
PGEN
Precigen Inc
PAPZIMEOS
For Treatment Of Adults With Recurrent Respiratory Papillomatosis
08/15/2025
7:40 AM
FDA approved

Precigen, Inc. announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP.

View
AKRO
Akero Therapeutics Inc
Efruxifermin (HARMONY)
Non-alcoholic steatohepatitis (NASH)
08/14/2025
3:35 AM
Publication

Akero Therapeutics, Inc. announced publication of 96-week results from the Phase 2b HARMONY trial in The Lancet.

View
VYD2311
Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
08/14/2025
4:50 PM
Provided Update

Invivyd, Inc. announced it has received and is aligned with advice from the U.S. Food and Drug Administration (FDA) on a compact and, therefore, rapid pathway to potential Biologics License Application (BLA) approval for Invivyd's novel monoclonal antibody (mAb) candidate VYD2311, for the prevention of COVID-19.

View
TIZAFTLSA
Tiziana Life Sciences PLC
Foralumab
Crohn's disease with decreases in the classic side effects of cytokine release syndrome
Phase 2a
08/14/2025
8:39 AM
Enrollment Update

Tiziana Life Sciences, Ltd. announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston, Massachusetts.

View
ENLV
Enlivex Therapeutics Ltd
Allocetra
Sepsis
Phase 2a
08/14/2025
8:08 AM
Presentation

Enlivex Therapeutics Ltd. announced it will host a webinar on Monday, August 18, 2025, at 8:00 AM Eastern Time to present and discuss 3-month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 trial, a double-blind, randomized, placebo-controlled multi-centered study.

View
SRRK
Scholar Rock Holding Corp
Apitegromab
Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
08/14/2025
8:07 AM
Published Results

Scholar Rock announced that positive study results from the pivotal Phase 3 SAPPHIRE trial (NCT05156320) were published in the peer-reviewed journal The Lancet Neurology.

View
BEAM
Beam Therapeutics Inc
BEAM-101
Sickle cell diseas
Regenerative Medicine Advanced Therapy (RMAT) Designation
08/14/2025
7:27 AM
Designation Grant

Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

View
ATHA
Athira Pharma Inc
ATH-1105
For Amyotrophic Lateral Sclerosis
Phase 1
08/14/2025
7:26 AM
presented results

Athira Pharma, Inc. presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in Dallas, Texas.

View
SMMT
Summit Therapeutics Inc
Ivonescimab
For Lung cancer
Phase 3
08/14/2025
7:23 AM
Data

Summit Therapeutics Inc. announced that data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer's (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona on Sunday, September 7, 2025, at 8:15am CET (2:15am ET).

View
VS-7375
In Advanced Solid Tumors
Phase 1/2
08/13/2025
6:09 PM
Efficacy and Safety Data

Verastem Oncology announced positive, updated safety and efficacy data and late-breaking presentation details of partner GenFleet Therapeutics' Phase 1/2 study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, known as VS-7375 outside of China, in advanced non-small cell lung cancer patients with a KRAS G12D mutation.

View
NUVL
Nuvalent, Inc.
zidesamtinib
ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib
Phase 1/2
08/13/2025
5:10 PM
Data

Nuvalent, Inc. announced that pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) from the global ARROS-1 Phase 1/2 clinical trial, in addition to preliminary data for TKI-naïve patients, will be presented as part of the Presidential Symposium at the IASLC 2025 World Conference on Lung Cancer (WCLC 2025). The conference is hosted by the International Association for the Study of Lung Cancer and is being held September 6-9, 2025, in Barcelona, Spain.

View
PRTCPTCHF
PureTech Health PLC
VE202
Inflammatory Bowel Disease
Phase 2
08/13/2025
5:08 PM
Endpoint Missed

PureTech Health plc announced that its candidate VE202 did not meet the primary endpoint in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC).

View
CELZ
Creative Medical Technology Holdings Inc
CELZ-201-DDT
For Chronic Back Pain
Fast Track Designation
08/13/2025
9:07 AM
Designation Grant

Creative Medical Technology announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

View
MDWD
MediWound Ltd
EscharEx
Chronic Wounds
08/13/2025
8:48 AM
Publication

MediWound Ltd. announced the publication of "The Correlation Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers: A Post Hoc Analysis of the ChronEx Multicenter Randomized Controlled Trial", in Advances in Wound Care, a leading peer-reviewed journal focused on tissue injury and repair.

View
MYNZ
Mainz Biomed N.V.
ColoAlert
In the early detection of cancer
08/13/2025
8:45 AM
Provided Update

Mainz Biomed N.V announced that ColoAlert®, its non-invasive colorectal cancer (CRC) screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices.

View
QUILT-106
Patients Treated With CD19 CAR-NK Therapy
Phase 1
08/13/2025
8:41 AM
Findings Update

ImmunityBio announced early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy.

View
Telitacicept
For the treatment of autoimmune diseases.
Phase 3
08/13/2025
8:39 AM
Primary Endpoint

Vor Bio announced that its collaborator, RemeGen Co., Ltd achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjögren's disease.

View
ALGS
Aligos Therapeutics Inc
ALG-000184
Hepatitis B
Phase 2b
08/13/2025
8:35 AM
Dose Update

Aligos Therapeutics, Inc. announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection.

View
INVA
Innoviva Inc
XACDURO®
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor
08/13/2025
8:23 AM
Provided Update

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. announced that two of the company's infectious disease therapies, ZEVTERA® (ceftobiprole medocaril sodium for injection) and XACDURO® (sulbactam/durlobactam for injection) have been nominated for the prestigious 2025 Prix Galien USA Award, "Best Pharmaceutical Product."

View
CTMX
CytomX Therapeutics Inc
CX-2051
A Probody® Antibody Drug Conjugate (ADC)
Phase 1
08/13/2025
8:18 AM
Provided Update

CytomX Therapeutics, Inc provided an update on the CX-2051 Phase 1 study to address certain recent social media posts.

View
TH104
For Chronic Pruritis in Primary Biliary Cholangitis (PBC)
08/13/2025
8:16 AM
Provided Update

Tharimmune, announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film.

View
APVO
Aptevo Therapeutics Inc
APVO442
Solid Tumors
08/13/2025
8:14 AM
Provided Update

Aptevo Therapeutics Inc. today reinforced the strategic importance of its preclinical asset APVO442-an investigational CD3-engaging bispecific antibody designed to treat prostate cancer.

View
MRK
Merck & Co Inc
KEYNOTE-689
In Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
Health Canada Approval
08/13/2025
7:20 AM
Approved

Merck announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.

View
OCGN
Ocugen Inc
OCU410ST
For Stargardt Disease
European Medicines Agency (EMA)
08/13/2025
7:17 AM
review

Ocugen, Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the ongoing pivotal confirmatory OCU410ST Phase 2/3 GARDian3 clinical trial for Stargardt disease and provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA).

View
GLSI
Greenwich LifeSciences Inc
GLSI-100
Breast cancer recurrences
08/13/2025
7:16 AM
Provided Update

Greenwich LifeSciences, Inc. announced the addition of clinical sites in Romania.

View
CGTX
Cognition Therapeutics, Inc.
CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.
Phase 2
08/12/2025
4:38 PM
Meeting minutes

Cognition Therapeutics, announced that it has received final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the end-of-Phase 2 meeting that was conducted on July 9, 2025.

View
INSM
Insmed Inc
Brensocatib
In Patients with Bronchiectasis
08/12/2025
4:35 PM
FDA approved

Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved first-in-class BRINSUPRI™ (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.

View
MIRA
MIRA PHARMACEUTICALS, INC.
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
08/12/2025
9:26 AM
Provided Update

MIRA Pharmaceuticals announced the acceptance of a second peer-reviewed manuscript describing its lead oral drug candidate, Ketamir-2, in Frontiers in Pharmacology.

View
SENTI-202
Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
08/12/2025
9:16 AM
Provided Update

Senti Biosciences, Inc announced that it participated in a Virtual Investor "What This Means" segment.

View
IGC-M3
Alzheimer's disease
08/12/2025
9:05 AM
Promising data

IGC Pharma, announced promising preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers of Alzheimer's disease.

View
AMPLIFY-201
In gastrointestinal tumors
Phase 1
08/12/2025
8:09 AM
Publication

Elicio Therapeutics, announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine.

View
AARD
Aardvark Therapeutic Inc
ARD-201
For the treatment of metabolic obesity and obesity-related conditions.
08/12/2025
8:06 AM
Positive Data

Aardvark Therapeutics, Inc. announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions.

View
AN2-502998
For Chagas Disease
08/12/2025
7:04 AM
Dose Update

AN2 Therapeutics, Inc. announced that it has completed dosing the first single ascending dose cohort in its Phase 1 first-in-human clinical trial evaluating the safety, tolerability, and pharmacokinetics of oral AN2-502998 in healthy volunteers.

View
OCUL
Ocular Therapeutix Inc
AXPAXLI
In Diabetic Retinopathy
08/12/2025
6:37 AM
Provided Update

Ocular Therapeutix, Inc. announced it has received written agreement regarding a registrational trial design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the Company's planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

View
MRK
Merck & Co Inc
EV-303
For Certain Patients with Muscle-Invasive Bladder Cancer
Phase 3
08/11/2025
4:57 PM
Top-line results

Merck announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

View
NVCT
Nuvectis Pharma, Inc.
NXP900
Novel inhibitor of the SRC family of kinases
Phase 1b
08/11/2025
4:44 PM
Provided Update

Nuvectis Pharma, Inc. announced the initiation of the Phase 1b program for NXP900.

View
TIZAFTLSA
Tiziana Life Sciences PLC
Foralumab
Crohn's disease with decreases in the classic side effects of cytokine release syndrome
Investigational New Drug (IND)
08/11/2025
9:02 AM
FDA approved

Tiziana Life Sciences, Ltd. is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA).

View
INO
Inovio Pharmaceuticals Inc
INO-3107
For the Treatment of Recurrent Respiratory Papillomatosis
08/11/2025
8:25 AM
Peer-reviewed data

INOVIO nnounced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with INO-3107 were published online in The Laryngoscope under the title "DNA Immunotherapy (INO-3107) Results in Long-term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)."

View
IOBT
IO Biotech
Cylembio
For the Treatment of First-line Advanced Melanoma
Phase 3
08/11/2025
8:08 AM
Top-line results

IO Biotech announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio® (imsapepimut and etimupepimut, adjuvanted).

View
Pressure-Enabled Drug DeliveryTM (PEDD)
For the treatment of patients with symptomatic thyroid disease.
08/11/2025
8:06 AM
Publication

TriSalus Life Sciences® Inc is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with symptomatic thyroid disease.

View
NRXP
NRx Pharmaceuticals
NRX-100
To treat acute depression and suicidality
Fast Track Designation
08/11/2025
8:04 AM
Designation Grant

NRx Pharmaceuticals, Inc. announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.

View
QNTM
Quantum BioPharma Ltd
Lucid-MS
For people to gain back mobility lost with multiple sclerosis (MS).
08/11/2025
7:48 AM
Provided Update

Quantum BioPharma Ltd. announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS.

View
IMAB
I-MAB
Givastomig
In patients with advanced cancers
Phase 1b
08/11/2025
7:12 AM
Enrollment Update

I-Mab announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in combination with nivolumab and mFOLFOX6, has been completed ahead of expectations.

View
GTBP
GT Biopharma Inc
GTB-3650
For Treatment of CD33+ Leukemia
Phase 1
08/11/2025
7:10 AM
Dose Update

GT Biopharma, Inc announced initiation of dosing in Cohort 3 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies.

View
STOK
Stoke Therapeutics Inc
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
Phase 3
08/11/2025
7:08 AM
Dosing Update

Stoke Therapeutics, Inc announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome.

View
AMPH
Amphastar Pharmaceuticals Inc
Venofer
In patients with chronic kidney disease (CKD).
08/11/2025
6:03 AM
FDA approved

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002.

View
NVSNVSEF
Novartis AG
ianalumab
In adults with active Sjögren's disease.
Phase 3
08/11/2025
3:47 AM
Top-line results

Novartis announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease.

View
NYXH
Nyxoah SA
Genio
For the Treatment of Obstructive Sleep Apnea
08/08/2025
4:53 AM
FDA approved

Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.

View
ARVN
Arvinas Inc
Vepdegestrant
For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
New Drug Application (NDA)
08/08/2025
4:51 AM
FDA Accepted

Arvinas, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vepdegestrant for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy.

View
CAPR
Capricor Therapeutics Inc
deramiocel
For the treatment of Duchenne muscular dystrophy (DMD)
Type A Meeting
08/08/2025
9:00 AM
FDA Meeting

Capricor Therapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

View
ASMB
Assembly Biosciences Inc
ABI-5366
For recurrent genital herpes.
08/08/2025
8:39 AM
Positive Results

Assembly Biosciences, Inc announced positive interim antiviral activity, clinical outcomes, safety and pharmacokinetic (PK) results from a Phase 1b study evaluating ABI-5366, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor, in participants seropositive for HSV type 2 (HSV-2) with recurrent genital herpes.

View
NTRB
Nutriband Inc
AVERSA
An abuse-deterrent fentanyl transdermal patch.
Type C Meeting
08/08/2025
8:36 AM
FDA GRANT

Nutriband Inc. announced that the United States Food and Drug Administration (US FDA) has granted a Type C Meeting for its lead product, AVERSA™ FENTANYL (abuse deterrent fentanyl transdermal system).

View
IXHL
Incannex Healthcare Limited
IHL-42X
Obstructive Sleep Apnoea (OSA)
Phase 2
08/08/2025
8:31 AM
Findings Update

Incannex Healthcare Inc announced new patient-reported outcome findings from a subset of participants in its RePOSA Phase 2 trial of IHL-42X for the treatment of obstructive sleep apnoea (OSA).

View
OBIO
Orchestra BioMed Holdings Inc
BACKBEAT
AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications.
08/08/2025
7:21 AM
FDA approved

Orchestra BioMed Holdings, announced the roll out of a protocol update, approved by the U.S. Food and Drug Administration ("FDA"), that significantly expands patient eligibility criteria for enrollment of the BACKBEAT study evaluating AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications.

View
PALI
Palisade Bio, Inc.
PALI-2108
For patients affected by UC.
08/07/2025
9:34 AM
New Data

Palisade Bio, Inc announced compelling new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 inhibitor, including positive topline results from its Phase 1b open-label cohort in patients with moderate-to-severe UC and colon tissue pharmacokinetic (PK) data from the Phase 1a multiple ascending dose (MAD) cohort.

View
VTVT
vTv Therapeutics Inc
Cadisegliatin
For Type 1 Diabetes
Phase 3
08/07/2025
8:38 AM
Provided Update

vTv Therapeutics Inc. announced the first study participant has been randomized in the Company's CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with type 1 diabetes (T1D).

View
SLS
SELLAS Life Sciences Group Inc
galinpepimut-S (GPS)
Targets the WT1 protein, which is present in an array of tumor types.
Phase 3
08/07/2025
8:35 AM
Analysis

SELLAS Life Sciences Group, Inc. announced that the Independent Data Monitoring Committee (IDMC) has completed a pre-specified analysis of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), and has issued a positive recommendation to continue the trial without modification.

View
FGENALPMFALPMY
FibroGen Inc
Astellas Pharma Inc
roxadustat
Anemia of chronic kidney disease (CKD)
Type C Meeting
08/07/2025
7:59 AM
Positive Feedback

FibroGen announced positive feedback from its Type C meeting with the FDA, supporting the advancement of roxadustat for the treatment of anemia in patients with LR-MDS and high RBC transfusion burden, based on a post-hoc subgroup analysis from the MATTERHORN Phase 3 trial.

View
CYB003
Major Depressive Disorder
08/07/2025
7:57 AM
Application Approved

Cybin Inc announced that its Clinical Trial Application ("CTA") has been approved by the Irish Medicines Board, acting as the reference Member state, to initiate the EMBRACE™ study in Ireland, Poland, and Greece.

View
LLY
Eli Lilly and Co
orforglipron
Orforglipron for the treatment of obesity and overweight
Phase 3
08/07/2025
6:24 AM
Top-line results

Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes.

View
OST-HER2
In patients with HER2-expressing solid tumors in breast cancer and other cancers
08/07/2025
6:22 AM
Provided Update

OS Therapies announced that it held a successful Scientific Advice Meeting with the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) in July and has submitted an invited Innovative Licensing and Access Pathway (ILAP) application to begin the regulatory process towards approval of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.

View
tegoprubart
For Type 1 Diabetes
Phase 1b
08/06/2025
5:43 PM
Updated data

Eledon Pharmaceuticals, announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients.

View
CMRXJAZZ
Chimerix Inc
Jazz Pharmaceuticals PLC
dordaviprone
treatment for recurrent H3 K27M-mutant diffuse glioma
08/06/2025
5:40 PM
FDA GRANT

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.

View
IMMX
Immix Biopharma, Inc.
NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.
08/06/2025
5:38 PM
Provided Update

Immix Biopharma, Inc. announced important updates about its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation.

View
RNXT
RenovoRx, Inc.
RenovoCath
Solid Tumors
08/06/2025
5:36 PM
Provided Update

RenovoRx, Inc. announced strong progress in its commercialization efforts, including its growing customer base and the hiring of experienced medical device sales leader Philip Stocton as Senior Director of Sales and Market Development to lead the execution of RenovoRx's commercialization efforts.

View
KROS
Keros Therapeutics Inc
KER-065
To treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins
08/06/2025
5:34 PM
Provided Update

Keros Therapeutics, Inc. announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065.

View
MAT
Mattel Inc
Barbie
type 1 diabetes (T1D)
08/06/2025
5:29 PM
Provided Update

Mattel, Inc announced a partnership between its iconic Barbie™ brand and Quo Beauty®, the beloved and multi-award-winning Canadian beauty brand developed by Shoppers Drug Mart®. Available, August 11 nationwide, the all-new line includes colour cosmetics, cosmetic accessories, and hair accessories, all inspired by the Barbie™ brand's notable impact on beauty.

View
CING
Cingulate Inc.
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
08/06/2025
9:13 AM
NDA Filing

Cingulate announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).

View
ACTU
Actuate Therapeutics Inc
elraglusib
In relapsed/refractory Ewing Sarcoma (r/r EWS).
Phase 1b
08/06/2025
9:12 AM
Trial Initiation

Actuate Therapeutics, Inc. announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte's PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy in advanced pancreatic adenocarcinoma.

View
MBRX
Moleculin Biotech Inc
Annamycin
Soft tissue sarcoma (STS) lung metastases
08/06/2025
9:11 AM
Presentation

Moleculin Biotech, Inc., announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which demonstrated significant efficacy against various primary and metastatic liver cancers, including hepatocellular carcinoma (HCC), colorectal liver metastases, and pancreatic ductal adenocarcinoma (PDAC) liver metastases.

View
ICU
SeaStar Medical Holding Corporation
NEUTRALIZE-AKI
In adults with acute kidney injury
08/06/2025
9:09 AM
Enrollment Plan

SeaStar Medical Holding announced that it has successfully reached enrollment of 125 patients in the NEUTRALIZE-AKI pivotal clinical trial. Additionally, it has activated Methodist Hospital Metropolitan of San Antonio, Texas, as its 16th clinical trial site.

View
LTRN
Lantern Pharma Inc
LP-184
Prostate cancer
Investigational New Drug (IND)
08/06/2025
8:22 AM
FDA Clearance

Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression.

View
BTAI
BioXcel Therapeutics Inc
BXCL501 (dexmedetomidine)
For dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist
08/06/2025
8:20 AM
Publication

BioXcel Therapeutics announced a publication in the peer-reviewed journal Frontiers in Pharmacology, entitled "Dexmedetomidine potently and reversibly regulates stress-mediated behaviors."

View
ADIL
Adial Pharmaceuticals Inc
AD04
Alcohol Use Disorder (AUD)
Phase 2
08/06/2025
8:17 AM
FDA Meeting

Adial Pharmaceuticals, Inc. announced the completion of a successful End of Phase 2 meeting (EOP2M) with the Food and Drug Administration (FDA). The FDA has provided input into the AD04 Phase 3 adaptive design clinical trial and the overall clinical program.

View
LNTH
Lantheus Holdings Inc
Piflufolastat F 18 (formerly 8F-DCFPyL)
Biochemically Recurrent Prostate Cancer (CONDOR)
New Drug Application (NDA)
08/06/2025
8:05 AM
FDA Accepted

Lantheus Holdings, announced that the Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for a new formulation of its F 18 PSMA imaging agent filed by its affiliate, Aphelion.

View
TEVATEVJF
Teva Pharmaceutical Industries Ltd
AJOVY (Fremanezumab-vfrm)
Comorbid depression, anxiety or hypertension, as well as migraine
08/06/2025
8:03 AM
FDA approved

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more.

View
DTIL
Precision BioSciences Inc
PBGENE-HBV
For chronic hepatitis B virus (HBV)
08/06/2025
7:59 AM
Results

Precision BioSciences, Inc announced ELIMINATE-B results as of the data cutoff of July 28, 2025.

View
CardiolRx
Acute Myocarditis
Phase 2
08/06/2025
7:53 AM
Top-line results

Cardiol Therapeutics Inc. announced topline results from ARCHER, the Company's Phase II clinical trial in patients with acute myocarditis.

View
GLPGGLPGF
Galapagos NV
GLPG5101
In patients with relapsed/refractory chronic lymphocytic leukemia
Regenerative Medicine Advanced Therapy (RMAT) Designation
08/06/2025
4:30 AM
Designation Grant

Galapagos NV announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).

View
URGN
UroGen Pharma Ltd
ZUSDURI
for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
08/05/2025
8:12 AM
Provided Update

UroGen Pharma announced the 24-month DOR of 72.2% (95% CI 64.1%, 78.8%) by Kaplan-Meier estimate in patients who achieved CR at three months from the Phase 3 ENVISION trial of ZUSDURI™ (mitomycin) for intravesical solution, a treatment for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

WINT
Windtree Therapeutics Inc
Istaroxime
Cardiogenic Shock in severe acute heart failure
08/05/2025
9:05 AM
Data

Windtree Therapeutics, announced that it has performed a planned interim analysis of the SEISMiC C Phase 2 study data evaluating istaroxime in SCAI Stage C cardiogenic shock which showed istaroxime had a similar profile to that seen in previous studies despite a greater severity of illness and being used in addition to currently available inotropes and vasopressors.

View
SENTI-202
Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Phase 2
08/05/2025
8:36 AM
Provided Update

Senti Biosciences, announced it has confirmed the recommended Phase 2 dose (RP2D) in its Phase 1 study of SENTI-202, the Company's potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).Inc.

View
NUWE
Nuwellis Inc
Aquadex SmartFlow®
For patients suffering from hypervolemia (fluid overload).
08/05/2025
8:25 AM
Provided Update

Nuwellis, Inc. announced that the first patients have been successfully treated with Aquadex® ultrafiltration therapy in a hospital-based outpatient setting.

View
CMND-100
For Treatment Of AUD
08/05/2025
8:24 AM
Approved

Clearmind Medicine Inc. announced that it has received Institutional Review Board (IRB) approval from Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

View
NPM-139
Subdermal GLP-1 implant in development for chronic weight management
Phase 1
08/05/2025
8:22 AM
Results

Vivani Medical, Inc. today reported results from the LIBERATE-1 clinical study, the Phase 1 study of the exenatide GLP-1 implant NPM-115 representing the first-in-human test of the Company's proprietary NanoPortal™ implant technology.

View
NUVB
Nuvation Bio Inc.
IBTROZI
In Advanced ROS1-Positive Non-Small Cell Lung Cancer
08/05/2025
8:20 AM
Data Presentation

Nuvation Bio Inc announced that new data will be presented at the IASLC 2025 World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025 in Barcelona, Spain, and the European Society of Medical Oncology Congress Meeting(ESMO) October 17–21, 2025 in Berlin, Germany.

View
IMMPPRRUF
Immutep Ltd
eftilagimod alpha
For cancer and autoimmune disease
08/05/2025
8:17 AM
Positive Feedback

Immutep Limited announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), for first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients who have PD-L1 expression below 1 (Combined Positive Score [CPS] <1).

View
COCP
Cocrystal Pharma Inc
CDI-988
For Pandemic Norovirus and Coronavirus
Phase 1
08/05/2025
8:06 AM
Presentation

Cocrystal Pharma, announces the presentation of favorable safety and tolerability data from a randomized, double-blinded, placebo-controlled Phase 1 study with its oral, direct-acting pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium (MHSRS), being held August 4-7 in Kissimmee, Florida. Inc

View
IVBIYIVBXF
Innovent Biologics Inc
Taletrectinib
ROS1-Positive Non-Small Cell Lung Cancer
08/05/2025
8:06 AM
Data Presentation

Nuvation Bio Inc. announced that new data will be presented at the IASLC 2025 World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025 in Barcelona, Spain, and the European Society of Medical Oncology Congress Meeting(ESMO) October 17–21, 2025 in Berlin, Germany.

View
AMRX
Amneal Pharmaceuticals Inc
CREXONT
For Treatment of Parkinson's Disease
08/05/2025
7:41 AM
Marketing authorization

Knight Therapeutics Inc., announced that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson's disease (PD), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.

View
ELI-002
For patients with mutant Kirsten rat sarcoma
08/05/2025
7:10 AM
Provided Update

Elicio Therapeutics, Inc. announced that following the Independent Data Monitoring Committee's ("IDMC") pre-specified interim review of the unblinded safety and efficacy data in the Company's Phase 2 AMPLIFY-7P study in mutant KRAS ("mKRAS")-driven pancreatic ductal adenocarcinoma ("PDAC"), the IDMC recommended that the trial continue to the final analysis without modifications.

View
Tecarfarin
For Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
08/05/2025
6:10 AM
Clinical Trial

Cadrenal Therapeutics, Inc announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis.

View
BMYBMYMP
Bristol-Myers Squibb Company
Breyanzi (lisocabtagene maraleucel)
Second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL)
supplemental Biologics License Applications (sBLA)
08/04/2025
4:54 PM
Application Accepted

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for Breyanzi® (lisocabtagene maraleucel; liso-cel) as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.

View
VRTX
Vertex Pharmaceuticals Inc
VX-993
For the Treatment of Acute Pain
Phase 2
08/04/2025
4:46 PM
Top-line results

Vertex Pharmaceuticals Incorporated announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery.

View
AIM
AIM ImmunoTech Inc
Ampligen
COVID-19 and Other Respiratory Viral Diseases
08/04/2025
9:22 AM
Provided Update

AIM ImmunoTech Inc today highlighted recent key financial milestones and firmly stated its focus on advancing clinical trials of Ampligen® for the treatment of pancreatic cancer, with the ultimate goal of achieving drug approval.

View
CASI
CASI Pharmaceuticals Inc
CID-103
Relapsed Or Refractory Multiple Myeloma
08/04/2025
9:07 AM
FDA Clearance

CASI Pharmaceuticals, Inc. announced FDA clearance of an IND application for CID-103, an anti-CD38 monoclonal antibody in adults with active and chronic active renal allograft antibody mediated rejection (AMR).

View
SONN
Sonnet BioTherapeutics Holdings Inc
SON-1010
Advanced Solid Tumors
08/04/2025
8:47 AM
Clinical Study

Sonnet BioTherapeutics announced the expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221).

View
Swoop® System Sequences
Portable MR Imaging® System
08/04/2025
8:12 AM
Enrollment Update

Hyperfine, Inc announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025.

View
TH104
For Chronic Pruritis in Primary Biliary Cholangitis (PBC)
08/04/2025
8:11 AM
Provided Update

Tharimmune, Inc. today issued a comprehensive corporate update highlighting significant advancements across its pipeline.

View
INMB
INmune Bio Inc
INKmune
High-Risk Myelodysplastic Syndrome (MDS)
Phase 1/2
08/04/2025
8:10 AM
Provided Update

INmune Bio Inc. is pleased to report that its Phase I/II trial (the "CaRe PC" trial) of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary endpoints and is now closed to further enrollment.

View
AIMD
Ainos, Inc.
VELDONA
Potential Treatment of Oral Warts in HIV-Seropositive
Taiwan's Food and Drug Administration (TFDA)
08/04/2025
8:08 AM
Approved

Ainos, Inc. announced that its investigational low-dose oral interferon-alpha drug candidate, VELDONA®, has received formal approval from Taiwan's Food and Drug Administration (TFDA) to initiate a clinical study for primary Sjögren's syndrome (pSS).

View
TMDX
TransMedics Group Inc
OCS™ Heart System
For patients with end-stage lung, heart, and liver failure
Investigational Device Exemption
08/04/2025
8:04 AM
Conditional approval

TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the initiation of its Next-Generation OCS ENHANCE Heart trial.

View
LCTX
Lineage Cell Therapeutics Inc
OPC1
Treatment of Chronic and Subacute Spinal Cord Injury
08/04/2025
8:03 AM
Provided Update

Lineage Cell Therapeutics, Inc. announced that the first-ever chronic spinal cord injury patient has been treated in the Company's DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study at UC San Diego Health.

View
DYN
Dyne Therapeutics Inc
DYNE-251
Duchenne Muscular Dystrophy
Breakthrough Therapy Designation
08/04/2025
7:36 AM
Designation Grant

Dyne Therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with Duchenne muscular dystrophy (DMD), amenable to exon 51 skipping.

View
DYN
Dyne Therapeutics Inc
DYNE-251
Duchenne Muscular Dystrophy
Biologics License Applications (BLA)
08/04/2025
7:37 AM
BLA Filing

Dyne Therapeutics, Inc announced that potential BLA submission for U.S. accelerated approval anticipated in early 2026 -

View
SAVA
Cassava Sciences Inc
Simufilam
Alzheimer's Disease
08/04/2025
7:38 AM
Positive Results

Cassava Sciences, Inc. today reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex (TSC)-related epilepsy.

View
BCDA
BioCardia Inc
CardiAMP
Designed to be a comprehensive biotherapeutic heart failure solution
08/04/2025
6:04 AM
Regulatory Update

BioCardia®, today provides the anticipated timing of regulatory activities seeking FDA and Japan PMDA approvals of its CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter.

View
ALLO
Allogene Therapeutics Inc
Cemacabtagene Ansegedleucel
For Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
08/01/2025
4:19 PM
Provided Update

Allogene Therapeutics, Inc announced that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen to be used in its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL).

View
XCUR
Exicure Inc
burixafor
In Multiple Myeloma
Phase 2
08/01/2025
4:14 PM
Provided Update

Exicure, Inc announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT).

View
BTAI
BioXcel Therapeutics Inc
IGALMI™
Sublingual film
Phase 3
08/01/2025
7:04 AM
Pivotal Study

BioXcel Therapeutics, announced completion of the last patient last visit (LPLV) in the pivotal Phase 3 SERENITY At-Home clinical trial.

View
VTRS
Viatris Inc
meloxicam
For the Treatment of Moderate-to-Severe Acute Pain
Phase 3
08/01/2025
4:07 PM
Abstract

Viatris announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025.

View
ARTL
Artelo Biosciences Inc
ART12.11
For overcoming problematic drug properties which allows for precise control over purity, potency, and consistency.
08/01/2025
7:48 AM
Provided Update

Artelo Biosciences, announced that it has received written scientific advice from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development and first-in-human (FIH) clinical study plans for ART12.11, a novel cocrystal of Cannabidiol (CBD) and Tetramethylpyrazine (TMP).

View

What is an FDA Calendar?

Biotech investing is risk-fraught, as stocks are at the mercy of several catalysts – most of which are make-or-break events, aka binary events. A prudent investment strategy is to make informed decisions, being in the know of when to expect these events, how these events will pan out and the potential stock reaction in the run-up to the event and post the event.

Benzinga’s FDA calendar is a meaningfully designed, user friendly, dynamically updated and simplistic investment tool that is a ‘must-have’ for those looking to make money from the volatility that is typic of trading in biotech stocks.

The calendar lists down all key catalysts that can materially impact stocks, including:

  • PDUFA dates, or in other words FDA decision dates
  • Filing schedules for regulatory applications such as new drug application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc
  • FDA decisions (approvals/complete response letter/delay)
  • According to special statuses for treatment options, including orphan drug designation, rare disease designation, accelerated approval, priority review etc.
  • FDA’s Advisory Committee, or Adcom, meetings
  • Review meetings with FDA (pre-investigational new drug application meetings, end-of-phase meetings, Type A, Type B and Type C meetings)
  • Decisions by overseas regulatory agencies
  • Clinical data readouts
  • Presentation of data at various scientific conferences.

The calendar allows data screening, based on company names or tickers, events, date-wise or based on a date range. They are designed to serve as a ‘one-stop shop’ for data needs of investors, both existing and potential, to capitalize on the opportunities these catalysts throw up or cut the losses from an adverse development. 

What is a Catalyst?

A catalyst is any event/development that has the potential to swing the stock, usually in an appreciable way, in either direction, depending on how it materializes. 

Biotech Stock Movers

Regulatory actions and clinical readouts are stock-moving catalysts. The magnitude of the impact is usually disproportionate. Most clinical-stage biotechs, or companies which are yet to commercialize a product, do not generate revenues. The exceptions are those which may have out-licensed therapies-in-development to another company and as a result generate revenues in the form of licensing revenues. So, it will be years of investment (time money and efforts) into drug development, which usually takes about 10-15 years, on the promise of generating future returns.

A promising outcome in a particular stage of drug development is perceived by the market as an incremental step in bringing the company closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.

Similarly, an unfavorable or a partially successful outcome could suggest all the investment the company may have made in the investigational therapy could go down the drain. Quite appropriately, investors punish the stock by selling it in droves.

PDUFA and Adcom events are binary events that have two outcomes, triggering moves in stock depending on which outcome materializes.

Stock Movers

Gainers

TickerCompany±%Buy Stock
Loading...
Get in real-time

Loser

TickerCompany±%Buy Stock
Loading...
Get in real-time

Frequently Asked Questions

Q

What is an FDA PDUFA date?

A

Prescription Drug User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an ‘approved’ decision, or a ‘complete response letter’ or a delay due to reasons specific to the company or extraneous to the company.

PDUFA was passed in the U.S. in 1992, which allows the FDA to collect fees from the sponsor company to fund the review process.

A CRL is issued by the FDA when it deems that the regulatory application is not complete in its current form. The deficiencies usually that lead to rejection could be the need for additional clinical studies to establish the efficacy and/or safety of the treatment option, problems with chemistry, manufacturing and controls, etc.

A delay in the review period may stem from the FDA needs additional time to review any additional data/information that may have been tabled subsequent to the submission of the regulatory application or the FDA’s inability to complete site inspections where the drug ingredients are being made etc.

The FDA may mention a specific date or a period (say Q1, Q2, Q3, Q4, first-half, second-half, the name of the month) as the timeline by which a decision will be given. If the FDA does not mention any timeline, the company may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn’t provide a timeline either, it is left to the investors to do the calculations.

Q

How long does an FDA approval take?

A

A regulatory application (NDA, sNDA, BLA, sBLA, etc.) is usually accepted for standard review or priority review. A standard review will mean the FDA has to hand out its verdict within 10 months of filing the application. The review window for a priority review gets shortened to six months.

Once a company files for a regulatory application, the FDA takes up to 60 days to respond with an ‘accepted for review’ or ‘refuse-to-file’ decision.

Q

How do you find FDA approvals?

A

A Catalysts Calendar is one way of tracking all the decisions in a single place. Usually, the FDA puts out a release and/or communicates to the company, which in turn will issue a press release.